BTK and lymphoma: The occurrence of primary resistance towards BTK inhibition due to oncogenic events targeting downstream effectors, such as CARMA1, as well as the acquisition of secondary resistance demonstrates the necessity of alternative therapeutic strategies and the rational stratification of patients regarding the mutational status of their lymphoid cancer [257].